Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer - Full Text View

Sponsored by:	Ottawa Health Research Institute
Information provided by:	Ottawa Health Research Institute
ClinicalTrials.gov Identifier:	NCT00260975

Purpose

Many breast cancer patients treated with chemotherapy complain of problems with concentration and memory. This has been referred to as “chemo fog”. The current study is investigating this phenomenon by measuring patients’ mental function prior to and after exposure to chemotherapy, and by comparing mental function in those patients who receive chemotherapy and those who do not.

Condition
Breast Cancer

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer Memory

U.S. FDA Resources

Study Type:	Observational
Study Design:	Psychosocial, Longitudinal, Defined Population, Prospective Study
Official Title:	A Prospective, Longitudinal Investigation of the Neuropsychological and Psychosocial Effects of Cancer Therapy

Further study details as provided by Ottawa Health Research Institute:

Estimated Enrollment:	150
Study Start Date:	June 2001
Estimated Study Completion Date:	June 2006

Detailed Description:

Many breast cancer patients treated with chemotherapy complain of problems with concentration and memory. This has been referred to as “chemo fog”. The current study will investigate this phenomenon by measuring neuropsychological functioning in early stage breast cancer patients prior to and after exposure to chemotherapy, and by comparing change in cognitive function in these patients who receive chemotherapy to similar breast cancer patients receiving hormonal therapy only, and to healthy women without breast cancer.

Eligibility

Ages Eligible for Study:	50 Years to 65 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

stage I or II breast cancer; woman; 50-65 years old; post-menopausal

Exclusion Criteria:

history of previous cancer or chemotherapy; significant neurological or psychiatric history

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260975

Sponsors and Collaborators

Ottawa Health Research Institute

Investigators

Principal Investigator:

Barbara Collins

OHRI

More Information

Study ID Numbers:	1999232-01H
Study First Received:	November 30, 2005
Last Updated:	December 22, 2005
ClinicalTrials.gov Identifier:	NCT00260975
Health Authority:	Canada: Health Canada

Keywords provided by Ottawa Health Research Institute:

breast cancer
chemotherapy
hormonal therapy
cognitive function
chemo fog

Study placed in the following topic categories:

Skin Diseases
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009